Subjects will be randomized into 4 study groups: 1. Placebo; 2. Anastrazole and Testosterone; 3. Dutasteride and Testosterone; and 4. Testosterone only. A 2 step euglycemic clamp, body composition by dual X-ray absorptiometry scan, hormone and lipid assays will be performed to monitor metabolic effects of each treatment group. We hypothesize that increasing testosterone levels would increase lean mass, decrease fat mass and improve insulin sensitivity. We further hypothesize that improvements in the metabolic profile would decrease with anastrazole and improve with dutasteride, given in conjunction with T administration.
1 Primary · 2 Secondary · Reporting Duration: 14 weeks
57 Total Participants · 4 Treatment Groups
Primary Treatment: Anastrazole and Testosterone · No Placebo Group · N/A
Age 24 - 51 · Male Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: